Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review

Эволюция подходов к производству рекомбинантных белков в фармацевтической промышленности: критический обзор
Yik-Ling Chew, Kai Bin Liew, Siew-Keah Lee, Hui Suan Ng, Phei Er Kee, Ching Siang Tan, Achuth Jayakrishnan, Wan Rosalina Wan Rosli, Ahmad Rashidi Mohamed Tahir, Fashli Syafiq Abd Razak, Mahenthiran Ramasamy
2024-01-31

metabolic engineeringrecombinant biopharmaceuticalsrecombinant protein productionsynthetic biologyupstream and downstream processing
Many beneficial proteins have limited natural availability, which often restricts their supply and thereby reduces their potential for therapeutic or industrial usage. The advent of recombinant DNA (rDNA) technology enables the utilization of different microbes as surrogate hosts to facilitate the production of these proteins. This microbial technology continues to evolve and integrate with modern innovations to develop more effective approaches for increasing the production of recombinant biopharmaceuticals. These strategies encompass fermentation technology, metabolic engineering, the deployment of strong promoters, novel vector elements such as inducers and enhancers, protein tags, secretion signals, synthetic biology, high-throughput devices for cloning, and process screening. This appraisal commences with a general overview regarding the manufacture of recombinant proteins by microbes and the production of biopharmaceuticals, their trends towards the development of biopharmaceuticals, and then discusses the approaches adopted for accomplishing this. The design of the upstream process, which also involves host selection, vector design, and promoter design, is a crucial component of production strategies. On the other hand, the downstream process focuses on extraction and purification techniques. Additionally, the review covers the most modern tools and resources, methods for overcoming low expression, the cost of producing biopharmaceuticals in microbes, and readily available recombinant protein products.
1
Downstream processing emphasizes extraction and purification strategies, while modern reviews address tools for cloning, screening, and overcoming low expression.
2
Microbial biopharmaceutical manufacturing is evaluated in terms of production costs and commercially available recombinant protein products.
3
Recombinant DNA technology enables microbial surrogate hosts to produce therapeutically and industrially valuable proteins with limited natural availability.
4
Recombinant biopharmaceutical production has advanced through fermentation optimization, metabolic engineering, strong promoters, engineered vectors, protein tags, secretion signals, and synthetic biology.
5
Upstream process design—including host, vector, and promoter selection—is identified as crucial for improving recombinant protein production.

Microbial production systems for recombinant biopharmaceutical proteins

Production strategies and process approaches for improving recombinant protein yield, expression, extraction, purification, and manufacturing efficiency

Publication Details
Publication Date
2024-01-31
Journal
Publisher
ISSN
Cited by
65
Access Type
Author Information
Authors
Yik-Ling Chew
Kai Bin Liew
Siew-Keah Lee
Hui Suan Ng
Phei Er Kee
Ching Siang Tan
Achuth Jayakrishnan
Wan Rosalina Wan Rosli
Ahmad Rashidi Mohamed Tahir
Fashli Syafiq Abd Razak
Mahenthiran Ramasamy
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%